Anula Jayasuriya - Director at Lineage Cell Therapeutics, Inc.

Insider Transactions and Holdings

Security	Num Shares	Value	Price $	Transaction Date	Ownership	Underlying Class	Underlying Amount
Common Shares, no par value	10K	$10.9K	$1.09	Dec 29, 2023	Direct
Stock Option (Right to Buy)	75K			Jul 1, 2024	Direct	Common Shares

Showing 1 to 2 of 2 entries

Sym	Class	Transaction	%	Value $	* Price $	Shares	Shares After	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.